Literature DB >> 21132325

Occurrence of neuronal dysfunction during the first 5 years of multiple sclerosis is associated with cognitive deterioration.

Wafaa Zaaraoui1, Françoise Reuter, Audrey Rico, Anthony Faivre, Lydie Crespy, Irina Malikova, Elisabeth Soulier, Patrick Viout, Yann Le Fur, Sylviane Confort-Gouny, Patrick J Cozzone, Jean Pelletier, Jean-Philippe Ranjeva, Bertrand Audoin.   

Abstract

Brain neuronal injury is present in patients suffering from multiple sclerosis (MS) from the earliest stage of the disease; however, the functional counterpart of early neuronal injury is largely unknown. The goal of this study was to assess the potential impact of early neuronal dysfunction affecting white matter (WM), grey matter (GM), or the cerebellum on cognitive deterioration and/or EDSS progression during the first 5 years of MS. Magnetic resonance spectroscopic (MRS) examinations and neuropsychological assessments were performed in 23 patients included after the first clinical attack of MS and 24 healthy controls. The same protocol was performed in patients after a follow-up of 5 years. Metabolic neuronal function was assessed in WM (splenium of corpus callosum), GM (dorsal posterior cingulate cortex), and the cerebellum by evaluating N-acetylaspartate (NAA) levels. During follow-up, 39% of patients showed cognitive deterioration and 43% showed a deterioration in their EDSS. Patients with cognitive deterioration had greater NAA level reductions during follow-up in the cerebellum (p = 0.003) and WM (p = 0.02) compared to patients without cognitive deterioration. In addition, patients with cognitive deterioration had higher progression of T2 lesion load (T2LL) during the follow-up period compared to patients without cognitive deterioration (p = 0.03). No differences between patients with and without EDSS progression in terms of NAA levels or T2LL were observed. The present longitudinal study found evidence that, during the first 5 years of MS, cognitive deterioration is associated with the progression of neuronal dysfunction and tissue injury as assessed by MRS and T2LL, respectively.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21132325     DOI: 10.1007/s00415-010-5845-4

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  30 in total

1.  Improved method for accurate and efficient quantification of MRS data with use of prior knowledge

Authors: 
Journal:  J Magn Reson       Date:  1997-11       Impact factor: 2.229

2.  An integrated program for amplitude-modulated RF pulse generation and re-mapping with shaped gradients.

Authors:  G B Matson
Journal:  Magn Reson Imaging       Date:  1994       Impact factor: 2.546

3.  Cognitive impairment in different MS subtypes and clinically isolated syndromes.

Authors:  Constantin Potagas; Erasmia Giogkaraki; Georgios Koutsis; Dimitrios Mandellos; Erifylli Tsirempolou; Constantin Sfagos; Demetris Vassilopoulos
Journal:  J Neurol Sci       Date:  2007-11-13       Impact factor: 3.181

4.  Magnetic resonance evidence of cerebellar cortical pathology in multiple sclerosis.

Authors:  Massimiliano Calabrese; Irene Mattisi; Francesca Rinaldi; Alice Favaretto; Matteo Atzori; Valentina Bernardi; Luigi Barachino; Chiara Romualdi; Luciano Rinaldi; Paola Perini; Paolo Gallo
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-12-03       Impact factor: 10.154

5.  Spectroscopic axonal damage of the right locus coeruleus relates to selective attention impairment in early stage relapsing-remitting multiple sclerosis.

Authors:  Marien Gadea; M Carmen Martínez-Bisbal; Luis Marti-Bonmatí; Raul Espert; Bonaventura Casanova; Francisco Coret; Bernardo Celda
Journal:  Brain       Date:  2003-09-23       Impact factor: 13.501

6.  MRI and localized proton MRS in early infantile form of neuronal ceroid-lipofuscinosis.

Authors:  S Confort-Gouny; B Chabrol; J Vion-Dury; J Mancini; P J Cozzone
Journal:  Pediatr Neurol       Date:  1993 Jan-Feb       Impact factor: 3.372

7.  Association of neocortical volume changes with cognitive deterioration in relapsing-remitting multiple sclerosis.

Authors:  Maria Pia Amato; Emilio Portaccio; Benedetta Goretti; Valentina Zipoli; Marco Battaglini; Maria Letizia Bartolozzi; Maria Laura Stromillo; Leonello Guidi; Gianfranco Siracusa; Sandro Sorbi; Antonio Federico; Nicola De Stefano
Journal:  Arch Neurol       Date:  2007-08

8.  MRI measures show significant cerebellar gray matter volume loss in multiple sclerosis and are associated with cerebellar dysfunction.

Authors:  V M Anderson; L K Fisniku; D R Altmann; A J Thompson; D H Miller
Journal:  Mult Scler       Date:  2009-05-22       Impact factor: 6.312

9.  Axonal damage but no increased glial cell activity in the normal-appearing white matter of patients with clinically isolated syndromes suggestive of multiple sclerosis using high-field magnetic resonance spectroscopy.

Authors:  M P Wattjes; M Harzheim; G G Lutterbey; L Klotz; H H Schild; F Träber
Journal:  AJNR Am J Neuroradiol       Date:  2007-09       Impact factor: 3.825

10.  Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.

Authors:  W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

View more
  6 in total

1.  Progress in multiple sclerosis research in the last year.

Authors:  Daniela Galimberti; Elio Scarpini
Journal:  J Neurol       Date:  2012-06-22       Impact factor: 4.849

2.  Metabolic profile of PML lesions in patients with and without IRIS: an observational study.

Authors:  Sarah Gheuens; Long Ngo; Xiaoen Wang; David C Alsop; Robert E Lenkinski; Igor J Koralnik
Journal:  Neurology       Date:  2012-08-22       Impact factor: 9.910

Review 3.  Impact of Pharmacotherapy on Cognitive Dysfunction in Patients with Multiple Sclerosis.

Authors:  Shumita Roy; Ralph H B Benedict; Allison S Drake; Bianca Weinstock-Guttman
Journal:  CNS Drugs       Date:  2016-03       Impact factor: 5.749

4.  Serial proton MR spectroscopy of gray and white matter in relapsing-remitting MS.

Authors:  Ivan I Kirov; Assaf Tal; James S Babb; Joseph Herbert; Oded Gonen
Journal:  Neurology       Date:  2012-11-21       Impact factor: 9.910

5.  IFN-gamma signaling in the central nervous system controls the course of experimental autoimmune encephalomyelitis independently of the localization and composition of inflammatory foci.

Authors:  Eunyoung Lee; Sarah Chanamara; David Pleasure; Athena M Soulika
Journal:  J Neuroinflammation       Date:  2012-01-16       Impact factor: 8.322

Review 6.  Symptom Interconnectivity in Multiple Sclerosis: A Narrative Review of Potential Underlying Biological Disease Processes.

Authors:  Tanuja Chitnis; Jo Vandercappellen; Miriam King; Giampaolo Brichetto
Journal:  Neurol Ther       Date:  2022-06-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.